Frederic currently serves as SVP Strategy & Business Development at Alexion. Prior to joining Alexion, he served as President and CEO of LogicBio. Previously, Frederic served as the President and Chief Operating Officer of aTyr Pharma Inc. He also served as President and CEO of Pervasis Therapeutics until its acquisition by Shire Pharmaceuticals where he had a critical impact on the development of the hereditary angioedema (HAE) franchise. Earlier in his career, for nearly a decade, Frederic served in various roles at Genzyme including Vice President and General Manager of the Cardiovascular Business Unit and held sales and marketing roles with a medical device company in France. He is also a member of the Board of Directors for Coave Therapeutics. Fred holds a B.S. in Physics from Paris University, a M.S. from ESC La Rochelle and an MBA from INSEAD.

Dr. Danos has over 30 years’ experience in gene therapy, as a scientist pioneering gene transfer technologies and as a leader in the biotech and pharmaceutical industry. He currently serves as the Chief Scientific Officer (CSO) of RegenxBio (Nasdaq: RGNX), a clinical stage biotechnology company developing a proprietary adeno-associated virus (AAV) gene delivery platform for the treatment of retinal, neurodegenerative and metabolic diseases.
Prior to RegenxBio, Olivier has undertaken a number of clinical research and executive leadership roles including Senior Vice President at Biogen and Kadmon Pharmaceuticals, Director of the Gene Therapy Consortium at UCL, CSO at Genethon, as well as Director of Research at the CNRS (Centre national de la recherche scientifique – The French National Centre for Scientific Research) and Principal Investigator at Institut Pasteur. Olivier completed his PhD at the University Paris Diderot.

Claudia is a scientist and entrepreneur with over 20 years’ research and industry experience. She most recently served as Senior Vice President of Portfolio Strategy at Astellas Pharma in Tokyo, Japan. Prior to this, Claudia co-founded Universal Cells, where she served as CEO until it was acquired by Astellas for over $100 million. Claudia also co-founded Halo-Bio RNAi Therapeutics and served as its Chief Scientific Officer.
Claudia holds a PhD in Molecular Biology from the University of Paris and an MBA in International Management from Ecole des Ponts Business School, Paris, France. She was awarded the 2018 EY Entrepreneur of the Year award in Life Sciences for the Pacific Northwest Region, USA.

Bruno is a Partner at Seroba Life Sciences. He has a background in venture capital and investment banking, with a focus on the pharmaceutical, biotechnology and medical device industries.
Bruno graduated in 1998 with a PharmD, from the Université René Descartes, Paris V and in the same year completed a master’s degree in Strategic Management at HEC.
Prior to joining the firm in 2017, Bruno was a Partner at Omnes Capital (Paris), in charge of life sciences investments for the venture capital team. His previous venture capital experience was at Atlas Venture (Paris/London) and CDP Capital (Paris/Montreal). He started his career in 1999 in London, in the healthcare teams of the investment banking divisions of Deutsche Bank and later Merrill Lynch. Bruno brings a wealth of experience and strong networks, particularly in continental Europe, where he is based.

Rodolphe has over 20 years’ experience in the pharma and biotech industry. Rodolphe joined Coave Therapeutics in 2020 from Enterome which he co-founded. During his tenure at Enterome, Rodolphe executed over 15 transactions, including major industrial partnerships with Takeda, J&J, BMS, Abbvie and Nestle Health Sciences, generating over €100 million in upfront, R&D payments, and equity investments. He was also actively involved in multiple fundraising rounds. Rodolphe has previously worked in business development at TcLand Expression and Genzyme, and as a sell-side equity analyst at Natixis Bank.
Rodolphe graduated with a degree in Biochemical Engineering from Polytech Marseille and is a Certified European Financial Analyst from EFFAS-SFAF.

Emmanuelle is Partner in the Seed Investment team at Novo Holdings, with over 16 years’ experience as a life science venture investor. Prior to Novo Holdings, Emmanuelle was Partner at Auriga Partners and oversaw the Seed Stage Investment Programme at Omnes Capital (formerly Crédit Agricole Private Equity). Emmanuelle has a PhD in Microbiology from the Universite Paris Cite and an MSM, Medical management from ESCP Business School.
Current positions: Member of the Board of Directors of Minervax, Draupnir, Corwave, Heparegenix, and BiOrigin.

Jean-François Morin is an Investment Director at Bpifrance with over a decade of experience in investment and finance. He specializes in life sciences, driving strategic investments in biotech and medtech companies. With a strong background in finance and venture capital, he has successfully managed and structured numerous investment deals. Jean-François currently serves on the Boards of ONA Therapeutics, Egle therapeutics, Orphalan, May Health and Pixee Medical. He began his carreer at MAZARS as a Financial Auditor, followed by a role at CDC Enterprises. He hold a Master’s degree in Finance from EDHEC Business School.

Dr. Danos is a pioneer in gene therapy with over 30 years of academic and industrial leadership experience. He is currently CSO at REGENXBIO, where he leads REGENXBIO’s scientific strategy. Prior to joining REGENXBIO, Dr. Danos was SVP, Cell and Gene Therapy at Biogen, where he led company efforts dedicated to identifying and developing new technologies for gene transfer and genome engineering. Dr. Danos also co-founded gene therapy company Lysogene and has undertaken clinical research and executive leadership roles including SVP, Molecular Medicine, Synthetic Biology and Gene Regulation at Kadmon Pharmaceuticals, Director of the Gene Therapy Consortium of the University College of London, Scientific Director at Genethon and Senior Director of Research at Somatix Therapy Corporation. Dr. Danos has directed research focused on gene therapy at the Necker-Enfants Malades Hospital in Paris, the French National Centre for Scientific Research and the Pasteur Institute in Paris.

Dr. Asokan is a leading expert in AAV vector biology and synthetic virology, with a focus on developing engineered AAVs to enable next-generation gene therapies. He serves as Professor and Director of Gene Therapy at Duke University School of Medicine, with appointments in the departments of Surgery, Biomedical Engineering, Molecular Genetics and Microbiology. His research group has pioneered several viral and RNA platform technologies to enable the translation of gene therapies. He is Director of the Danaher-Duke Beacon for Gene Therapy Innovation, a Novartis Global Scholar and has co-founded multiple biotech start-ups, including StrideBio (now part of Ginkgo Bioworks), Torque Bio and Lucidigm Therapeutics.

Dr. Mingozzi brings extensive expertise in gene therapy R&D and clinical translation, with a focus on developing gene therapies targeting the eye, liver and central nervous system. He has held key scientific roles at Spark Therapeutics, Genethon, INSERM and the Children’s Hospital of Philadelphia. His academic research advanced the understanding of immune responses to AAV vectors and strategies to improve the safety and efficacy of in vivo gene transfer. Dr. Mingozzi has contributed to pioneering gene therapy trials for bleeding disorders, inherited blindness (LUXTURNA®), and metabolic and neuromuscular diseases. His work spans delivery technologies, manufacturing, regulatory strategy and clinical development. Passionate about innovation and mentorship, he is dedicated to translating science into transformative therapies for patients.